BMJ 2002;325:1212-1213 ( 23 November )

Papers

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

Papers pp 1195, 1199

Louise Arseneault, lecturer ^a, Mary Cannon, Wellcome Trust advanced fellow ^b, Richie Poulton, director, Dunedin multidisciplinary health and development study ^c, Robin Murray, professor ^b, Avshalom Caspi, professor ^a, Terrie E Moffitt, professor ^a. 

^a SGDP Research Centre, King's College, London SE5 8AF, ^b Division of Psychological Medicine, King's College, ^c Dunedin Multidisciplinary Health and Development Research Unit, University of Otago, Dunedin, New Zealand

Correspondence to: T E Moffitt t.moffitt{at}iop.kcl.ac.uk

The strongest evidence that cannabis use may be a risk factor for later psychosis comes from a Swedish cohort study which found that heavy cannabis use at age 18 increased the risk of later schizophrenia sixfold. ^{1 2} This study could not establish whether adolescent cannabis use was a consequence of pre-existing psychotic symptoms rather than a cause. We present the first prospective longitudinal study of adolescent cannabis use as a risk factor for adult schizophreniform disorder, taking into account childhood psychotic symptoms³ antedating cannabis use.

View this table: [in this window] [in a new window]   Association between cannabis use in adolescence and schizophrenia and depressive symptoms and disorders at age 26 (n=759), controlling for childhood psychotic symptoms and use of other drugs in adolescence

	Methods and results

Top Methods and results Comment References

The Dunedin multidisciplinary health and development study (a study of a general population birth cohort of 1037 individuals born in Dunedin, New Zealand, in 1972-3)⁴ has a 96% follow up rate at age 26. It obtained information on psychotic symptoms at age 11 and drug use at ages 15 and 18 from self reports and assessed psychiatric symptoms at age 26 with a standardised interview schedule to obtain DSM-IV (diagnostic and statistical manual of mental disorders, 4th edition) diagnoses. We analysed data from a representative group of 759 (74%) living study members who had complete data on adult psychiatric outcomes, adolescent use of illicit substances, and childhood psychotic symptoms.

We divided the sample into three groups based on cannabis use at ages 15 and 18. The 494 controls (65.1% of the sample) had reported using cannabis "never" or "once or twice" at both ages; cannabis users by age 18 (236; 31.1%) first reported using cannabis "three times or more" at age 18; and cannabis users by age 15 (29; 3.8%) had reported using cannabis "three times or more" at age 15 (all of whom continued to use cannabis at age 18).

Psychiatric outcomes at age 26 were symptoms of schizophrenia and depression and diagnoses of schizophreniform disorder and depression.

Multiple linear regression analyses showed that cannabis users by age 15 and by age 18 had more schizophrenia symptoms than controls at age 26 (table). These results remained significant after psychotic symptoms at age 11 were controlled for. The effect was stronger with earlier use.

Logistic regression analyses showed that people who used cannabis by age 15 were four times as likely to have a diagnosis of schizophreniform disorder at age 26 than controls. After psychotic symptoms at age 11 were controlled for, the risk for adult schizophreniform disorder remained higher among those who used cannabis at age 15; however, this risk was reduced by 31% and was no longer significant.

Cannabis use by age 15 did not predict depressive outcomes at age 26. Use of other drugs in adolescence did not predict schizophrenia outcomes over and above the effect of cannabis use.

	Comment

Top Methods and results Comment References

Using cannabis in adolescence increases the likelihood of experiencing symptoms of schizophrenia in adulthood. Our findings agree with those of the Swedish study¹ and add three new pieces of evidence. Firstly, cannabis use is associated with an increased risk of experiencing schizophrenia symptoms, even after psychotic symptoms preceding the onset of cannabis use are controlled for, indicating that cannabis use is not secondary to a pre-existing psychosis. Secondly, early cannabis use (by age 15) confers greater risk for schizophrenia outcomes than later cannabis use (by age 18). The youngest cannabis users may be most at risk because their cannabis use becomes longstanding.⁵ Thirdly, risk was specific to cannabis use, as opposed to use of other drugs, and early cannabis use did not predict later depression. Our findings now require replication in large population studies with detailed measures of cannabis use and schizophrenia.

Although most young people use cannabis in adolescence without harm, a vulnerable minority experience harmful outcomes. A tenth of the cannabis users by age 15 in our sample (3/29) developed schizophreniform disorder by age 26 compared with 3% of the remaining cohort (22/730). Our findings suggest that cannabis use among psychologically vulnerable adolescents should be strongly discouraged by parents, teachers, and health practitioners. Policy makers and law makers should concentrate on delaying onset of cannabis use.

	Acknowledgments

We thank the Dunedin study members, data managers HonaLee Harrington and Barry Milne, study founder Phil Silva, and Air New Zealand. Helpful comments on earlier drafts were provided by Griffith Edwards.

Contributors: LA participated in the study design, analysed and interpreted the data, and wrote the first draft of the paper. MC and RP participated in the study design and assisted with the analysis and interpretation of the data and the writing of the paper. RM, AC, and TEM participated in the study design and assisted with the interpretation of the data and writing of the paper. RP, AC, and TEM coordinated the collection of the data. LA, RP, and TEM are guarantors of the study.

	Footnotes

Editorial by Rey and Tennant

Funding: The Dunedin Multidisciplinary Health and Development Research Unit and RP are supported by the New Zealand Health Research Council. This research received support from the Schizophrenia Research Fund, London (MC, AC, TEM), the UK Medical Research Council, the EJLB Foundation (MC) and from US-NIMH grants MH45070 (TEM) and MH49414 (AC). LA is supported by the Canadian Institute of Health Research. TEM is a Royal Society-Wolfson Merit Award holder.

Competing interests: None declared.

	References

Top Methods and results Comment References

1.	Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 1987; ii: 1483-1485.
2.	Strang J, Witton J, Hall W. Improving the quality of the cannabis debate: defining the different domains. BMJ 2000; 320: 108-110[Free Full Text].
3.	Poulton R, Caspi A, Moffitt TE, Cannon M, Murray RM, Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 2000; 57: 1053-1058[Abstract/Free Full Text].
4.	Silva PA, Stanton WR, eds. From child to adult: the Dunedin multidisciplinary health and development study. Auckland: Oxford University Press, 1996.
5.	Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997; 92: 279-296[CrossRef][ISI][Medline].

---

© BMJ 2002
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Schizophrenia

Marco M Picchioni and Robin M Murray
BMJ 2007 335: 91-95. [Extract] [Full Text] [PDF]

Cannabis and psychosis

David M Fergusson, Richie Poulton, Paul F Smith, and Joseph M Boden
BMJ 2006 332: 172-175. [Full Text] [PDF]

Cannabis use is a risk factor for schizophrenia
BMJ 2002 325: 0. [Full Text]

Cannabis and mental health

Joseph M Rey and Christopher C Tennant
BMJ 2002 325: 1183-1184. [Extract] [Full Text] [PDF]

Cannabis use and mental health in young people: cohort study

George C Patton, Carolyn Coffey, John B Carlin, Louisa Degenhardt, Michael Lynskey, and Wayne Hall
BMJ 2002 325: 1195-1198. [Abstract] [Full Text] [PDF]

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study

Stanley Zammit, Peter Allebeck, Sven Andreasson, Ingvar Lundberg, and Glyn Lewis
BMJ 2002 325: 1199. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Pearlson, G. D., Folley, B. S. (2008). Schizophrenia, Psychiatric Genetics, and Darwinian Psychiatry: An Evolutionary Framework. Schizophr Bull 34: 722-733 [Abstract] [Full text]  
• Agrawal, A., Pergadia, M. L., Saccone, S. F., Lynskey, M. T., Wang, J. C., Martin, N. G., Statham, D., Henders, A., Campbell, M., Garcia, R., Broms, U., Todd, R. D., Goate, A. M., Rice, J., Kaprio, J., Heath, A. C., Montgomery, G. W., Madden, P. A. F. (2008). An Autosomal Linkage Scan for Cannabis Use Disorders in the Nicotine Addiction Genetics Project. Arch Gen Psychiatry 65: 713-721 [Abstract] [Full text]  
• Miettunen, J., Tormanen, S., Murray, G. K., Jones, P. B., Maki, P., Ebeling, H., Moilanen, I., Taanila, A., Heinimaa, M., Joukamaa, M., Veijola, J. (2008). Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br. J. Psychiatry 192: 470-471 [Abstract] [Full text]  
• Potvin, S., Kouassi, E., Lipp, O., Bouchard, R.-H., Roy, M.-A., Demers, M.-F., Gendron, A., Astarita, G., Piomelli, D., Stip, E. (2008). Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 22: 262-269 [Abstract]  
• Houston, J. E., Murphy, J., Adamson, G., Stringer, M., Shevlin, M. (2008). Childhood Sexual Abuse, Early Cannabis Use, and Psychosis: Testing an Interaction Model Based on the National Comorbidity Survey. Schizophr Bull 34: 580-585 [Abstract] [Full text]  
• Macleod, J. (2007). Cannabis use and psychosis: the origins and implications of an association. Adv. Psychiatr. Treat. 13: 400-411 [Abstract] [Full text]  
• Archie, S., Rush, B. R., Akhtar-Danesh, N., Norman, R., Malla, A., Roy, P., Zipursky, R. B. (2007). Substance Use and Abuse in First-Episode Psychosis: Prevalence Before and After Early Intervention. Schizophr Bull 33: 1354-1363 [Abstract] [Full text]  
• ZAMMIT, S., SPURLOCK, G., WILLIAMS, H., NORTON, N., WILLIAMS, N., O'DONOVAN, M. C., OWEN, M. J. (2007). Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry 191: 402-407 [Abstract] [Full text]  
• Picchioni, M. M, Murray, R. M (2007). Schizophrenia. BMJ 335: 91-95 [Full text]  
• BARNETT, J. H., WERNERS, U., SECHER, S. M., HILL, K. E., BRAZIL, R., MASSON, K., PERNET, D. E., KIRKBRIDE, J. B., MURRAY, G. K., BULLMORE, ED. T., JONES, P. B. (2007). Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry 190: 515-520 [Abstract] [Full text]  
• Skosnik, P. D., Krishnan, G. P., Aydt, E. E., Kuhlenshmidt, H. A., O'Donnell, B. F. (2006). Psychophysiological Evidence of Altered Neural Synchronization in Cannabis Use: Relationship to Schizotypy. Am. J. Psychiatry 163: 1798-1805 [Abstract] [Full text]  
• Jones, R., Marcer, H., Haig, S. (2006). What paediatricians should know about young people and drugs in the UK. EDUCATION AND PRACTICE 91: ep81-ep86 [Full text]  
• Chong, M S, Wolff, K, Wise, K, Tanton, C, Winstock, A, Silber, E (2006). Cannabis use in patients with multiple sclerosis. Mult Scler 12: 646-651 [Abstract]  
• McArdle, P A (2006). Cannabis use by children and young people.. Arch. Dis. Child. 91: 692-695 [Abstract] [Full text]  
• Macleod, J., Hickman, M. (2006). Commentary: Understanding pathways to cannabis use and from use to harm.. Int J Epidemiol 35: 680-682 [Full text]  
• WILES, N. J., ZAMMIT, S., BEBBINGTON, P., SINGLETON, N., MELTZER, H., LEWIS, G. (2006). Self-reported psychotic symptoms in the general population: Results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br. J. Psychiatry 188: 519-526 [Abstract] [Full text]  
• MONSHOUWER, K., VAN DORSSELAER, S., VERDURMEN, J., BOGT, T. T., DE GRAAF, R., VOLLEBERGH, W. (2006). Cannabis use and mental health in secondary school children: Findings from a Dutch survey. Br. J. Psychiatry 188: 148-153 [Abstract] [Full text]  
• Fergusson, D. M, Poulton, R., Smith, P. F, Boden, J. M (2006). Cannabis and psychosis. BMJ 332: 172-175 [Full text]  
• Joffe, A., for the Committees on Substance Abuse and Adolesce, (2005). Response to the American Academy of Pediatrics Report on Legalization of Marijuana: In Reply. Pediatrics 116: 1257-1257 [Full text]  
• GREEN, B., YOUNG, R., KAVANAGH, D. (2005). Cannabis use and misuse prevalence among people with psychosis. Br. J. Psychiatry 187: 306-313 [Abstract] [Full text]  
• Henquet, C., Murray, R., Linszen, D., van Os, J. (2005). The Environment and Schizophrenia: The Role of Cannabis Use. Schizophr Bull 31: 608-612 [Abstract] [Full text]  
• Semple, D. M., McIntosh, A. M., Lawrie, S. M. (2005). Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19: 187-194 [Abstract]  
• Marlowe, K. (2005). Social development, urban environment and psychosis. Br. J. Psychiatry 186: 77-77 [Full text]  
• Johns, L. C., Cannon, M., Singleton, N., Murray, R. M., Farrell, M., Brugha, T., Bebbington, P., Jenkins, R., Meltzer, H. (2004). Prevalence and correlates of self-reported psychotic symptoms in the British population. Br. J. Psychiatry 185: 298-305 [Abstract] [Full text]  
• Leask, S. J. (2004). Environmental influences in schizophrenia: the known and the unknown. Adv. Psychiatr. Treat. 10: 323-330 [Abstract] [Full text]  
• Weiser, M., Reichenberg, A., Grotto, I., Yasvitzky, R., Rabinowitz, J., Lubin, G., Nahon, D., Knobler, H. Y., Davidson, M. (2004). Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study. Am. J. Psychiatry 161: 1219-1223 [Abstract] [Full text]  
• Joffe, A., Yancy, W. S., the Committee on Substance Abuse and Committee on, (2004). Legalization of Marijuana: Potential Impact on Youth. Pediatrics 113: e632-e638 [Abstract] [Full text]  
• Arseneault, L., Cannon, M., Witton, J., Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184: 110-117 [Abstract] [Full text]  
• Iversen, L. (2003). Cannabis and the brain. Brain 126: 1252-1270 [Abstract] [Full text]  
• (2003). Cannabis and Mental Disorders. JWatch Psychiatry 2003: 11-11 [Full text]  
• (2002). Cannabis and Mental Disorders. JWatch General 2002: 3-3 [Full text]  
• Rey, J. M, Tennant, C. C (2002). Cannabis and mental health. BMJ 325: 1183-1184 [Full text]  

Rapid Responses:

Read all Rapid Responses

early days

david h yates
bmj.com, 22 Nov 2002 [Full text]

Getting the right information for the debate

Francis T. Reilly
bmj.com, 23 Nov 2002 [Full text]

Specificity argument is unconvincing

Adam Jacobs
bmj.com, 25 Nov 2002 [Full text]

Psychosis - reason or consequence of cannabis use?

Anna Gombosova
bmj.com, 25 Nov 2002 [Full text]

Temporal relation between cannabis use and early onset schizophrenia

Martin Holtmann, et al.
bmj.com, 17 Dec 2002 [Full text]